<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20180201105400Z</creation_date><modification_date>D:20180705124500Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-04-283_h_w_dec_25.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 9.7.2018c(2018)4515 (final)</p></section><section><header>commission implementing decisionof 9.7.2018
 withdrawing, at the holder&apos;s request, the marketing authorisation granted by decision 
 c(2004)3160 for &quot;ariclaim - duloxetine hydrochloride&quot;, a medicinal product for human 
 use</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 9.7.2018
 withdrawing, at the holder&apos;s request, the marketing authorisation granted by decision 
 c(2004)3160 for &quot;ariclaim - duloxetine hydrochloride&quot;, a medicinal product for human 
 use</header><p>(text with eea relevance)(only the dutch text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1,having regard to the application submitted by eli lilly nederland b.v. on 7 june 2018 with a 
 view to the withdrawal of the marketing authorisation for the medicinal product &quot;ariclaim - 
 duloxetine hydrochloride&quot;,
 whereas:
 (1)
 the placing on the market of the medicinal product &quot;ariclaim - duloxetine 
 hydrochloride&quot;, which is entered in the community register of medicinal products 
 under the numbers eu/1/04/283 was authorised by commission decision 
 c(2004)3160 of 11 august 2004.
 (2)
 following the holder&apos;s request, that authorisation should be withdrawn,
 has adopted this decision:
 article 1at the holder&apos;s request, the marketing authorisation granted by decision c(2004)3160 of 11 august 2004 for the medicinal product &quot;ariclaim - duloxetine hydrochloride&quot; is withdrawn.
 article 2the withdrawal referred to in article 1 shall be applicable with effect from 7 august 2018.1oj l 136, 30.4.2004, p. 1.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>article 3this decision is addressed to eli lilly nederland b.v., papendorpseweg 83, 3528 bj utrecht, nederland.
 done at brussels, 9.7.2018
 for the commissionxavier prats monn√©
 director-general</p></section></body></xml>